Dynavax and Biological E announced agreement of Dynavax’s CpG 1018 adjuvant for Biological E’s COVID-19 vaccine candidate
On Jul. 6, 2021, Dynavax Technologies and Biological E announced the execution of a commercial supply agreement of…
-
-
Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA
On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP)…
-
HDT Bio received notice to proceed from FDA for U.S. phase 1 clinical trial of RNA COVID-19 vaccine
On Jul. 1, 2021, HDT Bio announced the U.S. Food and Drug Administration had reviewed the companyﾒs Investigational…
-
Investigational malaria vaccine gives strong, lasting protection
On Jun. 30, 2021, the National Institutes of Health announced two U.S. Phase 1 clinical trials of a…
-
Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
-
Gavi signed agreement with Clover Biopharmaceuticals for supply to COVAX
On Jun. 30, 2021, Gavi, the Vaccine Alliance, announced that it had signed an advance purchase agreement with…
-
India approves Moderna’s Covid-19 vaccine for emergency use
On Jun. 29, 2021, India announced it had authorized the emergency use of Moderna’s Covid-19 vaccine as it…
-
Altimmune announced update on AdCOVID phase 1 clinical trial
On Jun. 29, 2021, Altimmune provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19….
-
VBI Vaccines announced initial positive phase 1 data for its eVLP vaccine candidate against COVID-19
On Jun. 29, 2021, VBI Vaccines announced positive Phase 1 data from its Phase 1/2 trial of the…
-
Adjuvant developed with NIH funding enhanced efficacy of India’s COVID-19 vaccine
On Jun. 29, 2021, the National Institutes of Health announced that an adjuvant developed with its funding had…
-
Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
On Jun. 29, 2021, Paratek Pharmaceuticals announced it has delivered the first procurement of NUZYRA to the Biomedical…
-
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
-
First trial participants vaccinated with Oxford COVID-19 variant vaccine
On Jun. 28, 2021, the University of Oxford in partnership with AstraZeneca began vaccinations for a new phase…
-
Mixed Oxford/Pfizer vaccine schedules generated robust immune response against COVID-19
On Jun. 28, 2021, researchers running the University of Oxford-led Com-COV study reported that alternating doses of the…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Genomics | Life Science History | Medicine | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 PPE distribution
The COVID-19 PPE Distribution cartoon illustrates the confusion and complexity of distributing Personal Protective Equipment (PPE) to defend…
-
Oxford researchers identified levels of antibody protection required to prevent symptomatic COVID-19
On Jun. 25, 2021, researchers from the University of Oxford released their findings about the so-called ”correlates of…
-
NIH began sudy of COVID-19 vaccination during pregnancy and postpartum
On Jun. 23, 2021, the National Institutes of Health (NIH) announced that an observational study had begun to…
-
European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…
-
Construction of the Biologics Manufacturing Centre in Montreal completed
On Jun. 22, 2021, the National Research Council of Canada (NRC) announced it had completed construction of the…
-
WHO supported South African consortium to establish first COVID mRNA vaccine technology transfer hub
On Oct. 6, 2021, the World Health Organization (WHO) and its COVAX partners are working with a South…
-
Newly licensed U.S. manufacturing facility increased availability of Fluzone high-dose quadrivalent (influenza vaccine)
On Jun. 17, 2021, the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research granted…
-
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
REGEN-COV phase 3 RECOVERY trial met primary outcome, improving survival in Hospitalized COVID-19 patients
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Data published in NEJM showed Pfizer’s Tofacitinib met primary endpoint in Brazilian study in patients with COVID-19 pneumonia
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
-
Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…
-
Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
-
KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
On Jun. 14, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
-
University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award
On Jun. 14, 2021, University of British Columbia researchers Dr. Jayachandran Kizhakkedathu, Dr. Caigan Du and Dr. Christopher…
-
Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…
-
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
